The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
Active (recruiting)
Recruitment start date:
25/09/2014
Funder:
Cancer Research UK
Sponsor:
UCL
Chief Investigator:
Dr Mariam Jamal-Hanjani
Recruitment target:
500
EudraCT number:
N/A
Contact details:
ctc.peace@ucl.ac.uk
Lay summary:
PEACE
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
Description
Design: Posthumous Evaluation of Advanced Cancer Environment Study is a multi-centre prospective observational study
Treatment:
Blood samples will be taken at baseline and at follow-up time-points prior to death.
Tissue harvesting will be performed after death. Tissue will be collected from sites of tumour and normal tissue, guided by either imaging performed prior to the patient’s death or tissue harvest findings. This will entail: 
  • Sampling of all tumour tissue (this may involve the removal of organs to allow sampling)
  • Extensive background sampling of diseased organs (in the case of prostate/brain cancer this may involve sampling of the entire prostate/brain)
  • Smaller scale sampling of normal tissue from uninvolved sites
  • Taking blood samples.
In addition, bone marrow samples may be obtained. The following fluid may also be taken if present: cerebrospinal fluid, pleural fluid, pericardial fluid and urine. Any remaining tissue (with exception to prostate/brain) will be returned to the body. 

Key inclusion/exclusion criteria:
Inclusion criteria
  • Age 18 years or older
  • Confirmed diagnosis of any form of solid malignancy with metastatic disease (where the site of origin is known or unknown), with the exception of primary brain tumour in which there may not be evidence of metastatic disease
  • Oral and written informed consent from patient to enter the study and to undergo tumour harvesting after death or informed consent from a nominated representative or a person in a qualifying relationship after the patient has died
Exclusion Criteria
  • Medical or psychiatric condition that would preclude informed consent
  • History of intravenous drug abuse within the last 5 years
  • Confirmed diagnosis of known high-risk infections (e.g. HIV/AIDS-positive, hepatitis B/C, tuberculosis and Creutzfeldt-Jacob disease). Unless patient case is of particular scientific interest and agreed in advance with local mortuary staff and pathologist. 
Duration of recruitment: Until October 2023
Aim
The aim is to facilitate tissue donation from multiple tumour sites in the post-mortem setting and to perform 10-15 post-mortems each year at each site. 
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us